Skip Navigation LinksHome > March 2012 - Volume 21 - Issue 2 > Prevention of ER-negative breast cancer: where do we stand?
European Journal of Cancer Prevention:
doi: 10.1097/CEJ.0b013e32834c9c26
Review Article: Breast cancer

Prevention of ER-negative breast cancer: where do we stand?

Cazzaniga, Massimiliano; Bonanni, Bernardo

Collapse Box


Oestrogen receptor-negative and triple-negative breast cancers are types of aggressive tumours that account for approximately 30 and 15% of total breast cancers, respectively. Selective oestrogen receptor modulators and aromatase inhibitors are unable to treat and prevent these subtypes of mammary tumours. Thus, it is worth identifying new pathways, biomarkers, and agents that are effective in the treatment and prevention of these subtypes. Several classes of drugs have been studied, and many are still currently under investigation. We have attempted to conduct a state-of-the-art study on this important issue.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.